Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsInterest & Investment IncomeNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EBT (2020 - 2025)

Historic EBT for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to -$290.4 million.

  • Roivant Sciences' EBT fell 2381.79% to -$290.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$953.2 million, marking a year-over-year decrease of 12038.9%. This contributed to the annual value of -$681.6 million for FY2025, which is 11492.14% down from last year.
  • As of Q4 2025, Roivant Sciences' EBT stood at -$290.4 million, which was down 2381.79% from -$159.0 million recorded in Q3 2025.
  • Roivant Sciences' EBT's 5-year high stood at $5.2 billion during Q4 2023, with a 5-year trough of -$382.1 million in Q4 2022.
  • Over the past 5 years, Roivant Sciences' median EBT value was -$241.4 million (recorded in 2023), while the average stood at $114.1 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 139474.54% in 2021, then soared by 144882.37% in 2023.
  • Roivant Sciences' EBT (Quarter) stood at -$306.0 million in 2021, then dropped by 24.84% to -$382.1 million in 2022, then skyrocketed by 1448.82% to $5.2 billion in 2023, then plummeted by 104.55% to -$234.5 million in 2024, then fell by 23.82% to -$290.4 million in 2025.
  • Its EBT was -$290.4 million in Q4 2025, compared to -$159.0 million in Q3 2025 and -$269.3 million in Q2 2025.